NACK Inhibitors for Selective Notch Pathway Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds targeting the Notch pathway in cancer treatment often have off-target effects due to their broad substrate activity, particularly when targeting the γ-secretase enzyme complex, and there is a need for inhibitors that directly target the Notch transcription complex to effectively inhibit Notch-mediated transcription.
Innovation Solution
Development of specific compounds, such as those described in Formula (Ia), which inhibit the Notch activation complex kinase (NACK) by disrupting its recruitment to the Notch transcriptional complex, thereby blocking Notch-mediated transcriptional activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If γ-secretase inhibitors are used to block Notch pathway, then Notch-mediated transcription is inhibited, but off-target effects occur due to broad substrate activity
Solution Approach 1:
The patent extracts the specific kinase activity (NACK) from the broader γ-secretase complex by developing selective NACK inhibitors that do not target γ-secretase. This isolates the therapeutic action to the specific kinase responsible for Notch transcriptional activation, eliminating off-target effects associated with γ-secretase's multiple substrates
Solution Approach 2:
The invention applies local quality by designing inhibitors with specific molecular characteristics that target only NACK's kinase domain. The compounds exhibit selective binding properties tailored to NACK's active site, ensuring localized inhibition of Notch transcriptional activation without affecting other pathways
2Productivity
If small molecule inhibitors targeting γ-secretase are used, then Notch pathway is blocked, but the inhibitors affect multiple substrates beyond Notch
Solution Approach 1:
The patent introduces NACK as an intermediary target between γ-secretase and the Notch transcriptional complex. By inhibiting NACK, the compounds selectively block the kinase-mediated transcriptional activation step without interfering with γ-secretase's proteolytic function or other substrates, achieving precise control over Notch pathway output
3Reliability
If broad-spectrum Notch pathway inhibitors are used, then Notch transcription is suppressed, but non-Notch dependent cells are also affected
Solution Approach 1:
The patent segments the Notch pathway into distinct functional modules, targeting specifically the NACK kinase activity that drives transcriptional activation. This modular approach allows selective inhibition in Notch-dependent cancer cells while sparing normal cells that rely on different regulatory mechanisms or have lower NACK dependence
Data Source
AI summary
Disclosed herein are Notch transcriptional activation complex kinase (“MACK”) inhibitors, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein include compounds of Formula (Ia) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.